Clinical Trial Update: Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating NY-ESO-1–targeted T-cell therapy with or without decitabine in patients with NY-ESO-1–expressing advanced cancers, with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Melanoma
• Ovarian Cancer
• Peritoneal Cancer
• Synovial Sarcoma

Drugs mentioned

• Decitabine (Decitabine)
• NY-ESO-1 targeted TCR therapy (TCR-T therapy targeting NY-ESO-1)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-05-31